Literature DB >> 18985362

Restoring TGFbeta function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation.

Janindra Warusavitarne1, Fiona McDougall, Keshani de Silva, Rebecca Barnetson, Marinella Messina, Bruce G Robinson, Margaret Schnitzler.   

Abstract

BACKGROUND: TGFbeta is an important cell growth regulator which may have a role in metastasis formation. Microsatellite unstable (MSI-H) colon cancer serves as a unique model to demonstrate this as most MSI-H colon cancers have a mutation in the transforming growth factor beta receptor II (TGFbetaRII) gene and a low metastatic rate. AIMS: To demonstrate an increase in invasion and metastasis in a MSI-H colorectal cancer cell line with a known mutation in TGFbetaRII.
MATERIALS AND METHODS: By restoring the wild-type TGFbetaRII gene in the KM12C MSI-H colorectal carcinoma cell line with a known mutation in TGFbetaRII, we have demonstrated that both invasion and metastasis in this cell line was significantly increased. A mouse metastatic model have shown that liver metastases were increased in mice inoculated with cells containing a wild-type TGFbetaRII gene (42% for the transfected group compared with 15% for the control group; p = 0.0379), despite a reduction in the size of primary tumours.
CONCLUSIONS: This study highlights an important mechanism which may contribute to the low metastatic rate of MSI-H colon cancers and demonstrates the importance of TGFbeta signalling in metastasis formation. Previous studies involving breast cancer cell lines have shown that blocking TGFbeta signalling results in a reduction in metastasis formation. This study is the first study to use a cell line with a low metastatic rate and TGFbetaRII mutations to demonstrate that restoring TGFbeta signalling increases the metastatic rate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985362     DOI: 10.1007/s00384-008-0606-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  33 in total

Review 1.  Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer.

Authors:  Peter M Siegel; Joan Massagué
Journal:  Nat Rev Cancer       Date:  2003-11       Impact factor: 60.716

2.  Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops.

Authors:  J S de Jong; P J van Diest; P van der Valk; J P Baak
Journal:  J Pathol       Date:  1998-01       Impact factor: 7.996

3.  Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model.

Authors:  Jennifer A Tuxhorn; Stephanie J McAlhany; Feng Yang; Truong D Dang; David R Rowley
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

4.  Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion.

Authors:  G Portella; S A Cumming; J Liddell; W Cui; H Ireland; R J Akhurst; A Balmain
Journal:  Cell Growth Differ       Date:  1998-05

Review 5.  TGF-beta signaling in cancer--a double-edged sword.

Authors:  R J Akhurst; R Derynck
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

6.  Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.

Authors:  M A Rowland-Goldsmith; H Maruyama; T Kusama; S Ralli; M Korc
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

Review 7.  Tumor suppressor activity of the TGF-beta pathway in human cancers.

Authors:  S D Markowitz; A B Roberts
Journal:  Cytokine Growth Factor Rev       Date:  1996-06       Impact factor: 7.638

8.  Clues to the pathogenesis of familial colorectal cancer.

Authors:  L A Aaltonen; P Peltomäki; F S Leach; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; S M Powell; J Jen; S R Hamilton
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

9.  Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-beta1.

Authors:  K Kitagawa; A Murata; N Matsuura; K Tohya; S Takaichi; M Monden; M Inoue
Journal:  Int J Cancer       Date:  1996-03-28       Impact factor: 7.396

10.  Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma.

Authors:  N Ito; S Kawata; S Tamura; Y Shirai; S Kiso; H Tsushima; Y Matsuzawa
Journal:  Cancer Lett       Date:  1995-02-10       Impact factor: 8.679

View more
  5 in total

1.  Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Authors:  Catherine E Gatza; Alisha Holtzhausen; Kellye C Kirkbride; Allyson Morton; Michael L Gatza; Michael B Datto; Gerard C Blobe
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

2.  Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.

Authors:  George S Karagiannis; Ann Treacy; David Messenger; Andrea Grin; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2014-04-19       Impact factor: 6.603

Review 3.  How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression.

Authors:  Zhongyan Wang; Megan Snyder; Jessica E Kenison; Kangkang Yang; Brian Lara; Emily Lydell; Kawtar Bennani; Olga Novikov; Anthony Federico; Stefano Monti; David H Sherr
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 6.208

4.  Loss of MMR and TGFBR2 Increases the Susceptibility to Microbiota-Dependent Inflammation-Associated Colon Cancer.

Authors:  Elena Tosti; Ana S Almeida; Tam T T Tran; Mariel Barbachan E Silva; Pilib Ó Broin; Robert Dubin; Ken Chen; Amanda P Beck; Andrew S Mclellan; Eduardo Vilar; Aaron Golden; Paul W O'Toole; Winfried Edelmann
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-06-07

Review 5.  Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.

Authors:  Vito Amodio; Gianluca Mauri; Nicole M Reilly; Andrea Sartore-Bianchi; Salvatore Siena; Alberto Bardelli; Giovanni Germano
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.